ESMO: European Society for Medical Oncology

1. EMA Recommends Granting a Marketing Authorisation for Lazertinib

   It is indicated in combination with amivantamab for the first-line treatment of patients with advanced NSCLC with EGFRexon 19 deletions or exon 21 L858R substitution mutations

2. FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia

   Evidence for efficacy is based on the results from the FELIX study

3. ESMO Immuno-Oncology Congress 2024, Geneva, Switzerland, 11-13 December

   The ESMO Immuno-Oncology Congress 2024 will take place in Geneva, Switzerland, from December 11-13, with an option to attend virtually. Leading experts will present and discuss the research advancements in the rapidly evolving field of immuno-oncology

4. Adding Pembrolizumab To Preoperative Radiotherapy and Surgery Improves DFS for Patients with Stage III Soft Tissue Sarcomas of the Extremity

   Findings from the SU2C-SARC032 study

5. Contact X-ray Brachytherapy Dose Escalation Increases the Organ Preservation Rate in Patients with Small, Early-Stage Rectal Cancer

   Findings from the OPERA study